AlphAIAlphAI — Financial news for AI agents
investing.comOCT 52 min read$AMGN

Cantor Fitzgerald reiterates Amgen stock Neutral rating at $400

Cantor Fitzgerald maintained a Neutral rating on Amgen (AMGN) with a $400 price target, citing strong commercial execution and revenue growth. Amgen's stock trades at $403, with a P/E ratio of 25.1 and PEG ratio of 0.79. Recent trial results for dazodalibep showed positive outcomes, leading to mixed analyst reactions and adjusted price targets.

Original reporting
investing.com
Published Oct 5, 2026, 12:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 12:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$AMGN
Bullish
high confidence
Mentioned
$AMGN
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AMGNBullishHigh
01

Why it matters

The trial data provides a fresh catalyst that could shift sentiment and price action for Amgen and peers.

02

Market read

Positive Phase 3 data for a new drug is a high‑impact biotech catalyst, likely driving short‑term price gains.

03

What to watch

Pricing strategy and market competition for Sjögren’s disease therapies may temper upside.

Relevance 7/10Novelty 9/10Timing: today

Background

Analyst Cantor Fitzgerald reiterated a Neutral rating on Amgen with a $400 target; other firms adjusted targets after the trial news.

Company-level read

Ticker impact

$AMGNBullishHigh confidence
Context

Amgen announced positive Phase 3 trial results for dazodalibep in systemic Sjögren’s disease, prompting analyst rating updates.

Expected impact

upward pressure as the market prices in the successful trial outcomes

Evidence & confidence

Phase 3 success is a material catalyst for a biotech; analysts raised price targets, indicating near‑term buying interest.

Market effects

Sector

Biotech sector may see broader optimism on trial successes.

Regional

U.S. biotech stocks could rally in early trading.

Global

Potential impact on global pharma pipelines and competitor valuations.

Counterpoint

What could challenge this read

If regulatory scrutiny intensifies or data replication fails, the rally could be short‑lived.

Key entities

  • company
    Amgen Inc.

    Biopharma company reporting trial results.

  • analyst_firm
    Cantor Fitzgerald

    Reiterated Neutral rating on Amgen.

Read at source← All news

Related articles

OCT 6
$AMGNHighAI 9/10

Amgen’s ‘Imdelltra’ breaks ‘1-year survival barrier in SCLC – “i didn’t know it would be this good”

Amgen's Imdelltra (tarlatamab) showed significant results in a Phase 3 trial for small cell lung cancer (SCLC), extending median overall survival to 13.6 months, a 5.3-month improvement over chemotherapy. The trial, involving 509 patients, demonstrated a 40% reduction in death risk. Imdelltra is already approved in Korea for extensive-stage SCLC and has expanded indications.

thebionews.net3 min
OCT 5
$AMGNMedAI 9/10

Phase 3 Trial Shows Adding Imdelltra to First-Line Treatment Helps Patients With SCLC Live Longer

Amgen's phase 3 trial (DeLLphi-305) showed that adding Imdelltra (tarlatamab) to Imfinzi (durvalumab) as maintenance therapy improved overall and progression-free survival for extensive-stage small cell lung cancer (ES-SCLC) patients compared to Imfinzi alone. The trial enrolled 563 patients, and no new safety concerns were identified. Full results are pending. Imdelltra is not yet approved for this use.

curetoday.com3 min
OCT 3
$ABBVMed

AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot

The Trump administration selected 10 drugmakers, including AbbVie, Amgen, Pfizer, and GSK, for a 340B rebate pilot program starting January 1. The program tests a rebate model for 21 discounted drugs under the 340B program. The HRSA oversees the initiative, aiming to address compliance proactively. The program is contentious, with pharmaceutical companies and hospitals disputing its impact.

tradingview.com2 min
OCT 2
$NVSHighAI 8/10

Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer

Novartis' ianalumab and Amgen's dazodalibep met primary endpoints in late-stage trials for Sjögren disease, with Novartis receiving FDA breakthrough therapy designation. RemeGen's telitacicept was approved in China. Sjögren disease patients incur higher healthcare costs, and current treatments focus on symptom relief.

ajmc.com3 min
OCT 1
$AMGNMed

Drugmakers Turn to Proteomics to Map How Medicines Work

Drugmakers are increasingly using proteomics to study protein-level pathways of drug effects. Amgen, AstraZeneca, Johnson & Johnson, and MSD are involved in a UK Biobank project. In Korea, Bertis' proteomics tech was used in Hanmi Pharmaceutical's obesity drug research. The global proteomics market is expected to grow to $97.7B by 2033, per Grand View Research.

en.sedaily.com2 min